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Abstract: In this paper we develop a Bayesian analysis to estimate the disease prevalence, the sensitivity and speciﬁ  city of 
three cervical cancer screening tests (cervical cytology, visual inspection with acetic acid and Hybrid Capture II) in the 
presence of a covariate and in the absence of a gold standard. We use Metropolis-Hastings algorithm to obtain the posterior 
summaries of interest. The estimated prevalence of cervical lesions was 6.4% (a 95% credible interval [95% CI] was 3.9, 
9.3). The sensitivity of cervical cytology (with a result of  ASC-US) was 53.6% (95% CI: 42.1, 65.0) compared with 
52.9% (95% CI: 43.5, 62.5) for visual inspection with acetic acid and 90.3% (95% CI: 76.2, 98.7) for Hybrid Capture II 
(with result of 1 relative light units). The speciﬁ  city of cervical cytology was 97.0% (95% CI: 95.5, 98.4) and the speci-
ﬁ  cities for visual inspection with acetic acid and Hybrid Capture II were 93.0% (95% CI: 91.0, 94.7) and 88.7% (95% CI: 
85.9, 91.4), respectively. The Bayesian model with covariates suggests that the sensitivity and the speciﬁ  city of the visual 
inspection with acetic acid tend to increase as the age of the women increases.
The Bayesian method proposed here is an useful alternative to estimate measures of performance of diagnostic tests in the 
presence of covariates and when a gold standard is not available. An advantage of the method is the fact that the number of 
parameters to be estimated is not limited by the number of observations, as it happens with several frequentist approaches. 
However, it is important to point out that the Bayesian analysis requires informative priors in order for the parameters to be 
identiﬁ  able. The method can be easily extended for the analysis of other medical data sets.
Keywords: Bayesian analysis, diagnostic tests, latent variables, cervical cytology, visual inspection with acetic acid, Hybrid 
Capture II
1. Introduction
The sensitivity (Se) and the speciﬁ  city (Sp) are the two most common measures of the performance of 
a diagnostic test, where Se is the probability of a diseased individual to be correctly identiﬁ  ed by the test 
while Sp is the probability of an individual without the disease (or condition) of interest to be correctly 
identiﬁ  ed by the same test. When the outcomes of the diagnostic test are represented in a continuous 
scale, a cut-off value should be chosen in order to determine when an individual is classiﬁ  ed as positive 
or negative. Generally, individuals with test outcome larger or at least equal to this ﬁ  xed cut-off are 
classiﬁ  ed as positive while individuals with test outcomes inferior to this ﬁ  xed cut-off are classiﬁ  ed as 
negative.
Although the real disease status of the individual could be veriﬁ  ed by a procedure generically denom-
inated gold standard, it is common to ﬁ  nd situations where a proportion of the sampled individuals can-
not be veriﬁ  ed on their real disease status. The problem can occur especially when the gold standard is 
an invasive and/or risky procedure and the deﬁ  nitive veriﬁ  cation for apparently healthy individuals is 
thus neither practical nor ethical. In order to overcome this problem, many studies on the evaluation of 
the diagnostic test are carried out by considering only veriﬁ  ed individuals. However, this approach can 
lead to measures that are usually biased, leading to studies denominated veriﬁ  cation bias or workup bias. 
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Unbiased estimators for Se and Sp are introduced 
by Begg and Greenes [1] and Zhou [2].
Another problem appears when all individuals 
can not be veriﬁ  ed by a gold standard. This occurs 
when there is not a deﬁ  nitive test for detection of the 
disease or the veriﬁ  cation by a gold standard is an 
impracticable procedure according to its cost, acces-
sibility or risks. In this situation, maximum likeli-
hood estimators are proposed by Hui and Walter [3]. 
However, these estimators are reasonable only in 
situations where the number of observations is larger 
or equal to the number of parameters, which is not 
our case, as we will see later. Free of this limitation, 
a Bayesian approach was introduced by Joseph et al. 
[4]. However, the method of Joseph et al. [4] do not 
consider the presence of covariates, which are very 
common on data from diagnostic test studies.
The objective of the present study is to verify 
the performance measures of cervical cytology, 
Hybrid Capture II (HC II) and visual inspection 
with acetic acid (VIA) in the detection of cervical 
precursor lesions, using a Bayesian statistical 
method that allows for the estimation of these 
measures, although part of the sampled women was 
not veriﬁ  ed by a gold standard. We also consider 
the presence of covariates in our study. Since 
Bayesian methods are based on incorporation of 
historical information and expert opinion into the 
modelling strategy (the called prior information), 
these elements could be too subjective, with source 
for other bias. In other words, inadequate prior 
information can imply in a biased estimator. 
However, a careful verification of the prior 
information and a subsequent analysis of its changes 
in the outcomes can result in reasonable estimates 
for the tests performance measures.
Thus, the new methodological contribution of the 
present paper is an extension of the Bayesian method 
proposed by Joseph et al. [4] for estimating the per-
formance measures of screening tests introducing a 
vector of covariates. The rest of the paper is organized 
as follows. In Section 2, we discuss the deﬁ  nition of 
a gold standard in accuracy studies of cervical cancer 
screening tests. In Section 3, there is a description of 
the method of Joseph et al. [4] for estimating Se and 
Sp related to two diagnostic tests in the absence of a 
gold standard. We also introduce in this section the 
notation used in the paper. In the following, we intro-
duce the methodology for estimating Se and Sp in the 
presence of a covariate. The cervical cancer screening 
data set is described in Section 4. The application of 
the proposed methodology on the analysis of the data 
set is presented in Section 5. Concluding remarks are 
given in Section 6.
2. Accuracy of Cervical Cancer 
Screening Tests
South and Central America have some of the highest 
incidence rates for cervical carcinoma in the world, 
ranging from 30/100,000 women to 40/100,000 
women, or three to four times the incidence in devel-
oped countries [5]. In Brazil, crude estimates of 
incidence and mortality are given by 19,82/100,000 
and 4,49/100,000 women, respectively [6]. Thus, it 
is strongly justiﬁ  ed to analyze the accuracy of dif-
ferent diagnostic tools for cervical carcinoma and 
their efﬁ  cacy in screening programs.
In assessing the accuracy of cervical cancer screen-
ing tests, it is not straightforward to deﬁ  ne an ideal 
gold standard. In many studies, the gold standard for 
evaluating the accuracy of screening tests in detecting 
true positive lesions is histopathology. If biopsies are 
not obtained, colposcopy is accepted as the ﬁ  nal diag-
nosis. However, colposcopy can give many false 
negative results when used to discriminate between 
normal and abnormal tissues (see, for example, 
Mitchell et al. 1998 and Hopman et al. 1998) [7,8].
The reference test used in these studies, deﬁ  ned 
by the results of histology or colposcopy, is thus 
subject to errors and its estimates for sensitivity and 
speciﬁ  city can be biased. Another type of bias is 
evident when only a part of the sampled individuals 
will have their real disease status conﬁ  rmed by the 
biopsy and the remainders are not included in the 
calculations of the sensitivity and speciﬁ  city. This 
occurs principally when only the women with posi-
tive result for one or more diagnostic tests (or with 
positive clinical signals) are submitted to the gold 
standard and this selection results in an overestimated 
sensitivity and an underestimated speciﬁ  city [9].
Despite of the appearance of new methods devel-
oped to estimate the sensitivity and speciﬁ  city of 
screening tests without a gold standard [10] or in the 
presence of the veriﬁ  cation bias [11], many studies on 
the accuracy of cervical cancer screening tools present 
biased results due to the limitations of the proposed 
gold standard. For example, in a recent meta-analysis 
of the studies on performance of conventional cervical 
cytology, McCrory et al. (1999) evaluated 939 studies, 
where 84 took care of the standards established by the 
authors to guarantee the quality of the results. Of these 
84 studies, only three did not have their results affected 
by the veriﬁ  cation bias [12].
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Many studies are introduced in the literature in 
the absence of a gold standard. For instance, Hui and 
Walter (1980) derived equations that compute 
estimates and standard errors of sensitivity, speciﬁ  city 
and prevalence, without considering a reference test 
[3]. Joseph et al. (1995) introduced a Bayesian model 
using latent variables [4], and Dendukuri and Joseph 
(2001) extended this method to account for 
conditional dependence between the diagnostic tests 
[13]. Other important statistical contributions were 
provided by Faraone and Tsuang (1994) [14], Qu 
et al. (1996) [15] and Hadgu and Qu (1998) [16].
3. The Bayesian Framework
Considering k diagnostic tests, let Tm = 1 if the 
result of test m is positive and Tm = 0 if the result 
of test m is negative, for m = 1, ..., k. Let Sem and 
Spm be the sensitivity and the speciﬁ  city of the test 
m, respectively and let g be an observation of 
a binary latent variable G, introduced in the model 
aiming to simulate a non-observable gold standard 
[17]. Denoting the set of the observations and 
this latent variable for the i-th individual 
by xi
T
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assuming that the test outcomes are independents. 
We have 2k + 1 parameter to be estimated, or say, 
k pairs (Sem,  Spm), and the prevalence p. The likeli-
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The latent variable G, following the Bayes 
equation, has a Bernoulli distribution, that is,
Considering beta prior densities Beta(αθ , βθ) for 
all parameters in θ, where αθ and βθ generically 
denotes ﬁ  xed hyperparameters and combining the 
likelihood function for θ (1) with the prior densities, 
we use the Gibbs sampling algorithm [18,19] to 
simulate samples for the posterior distribution for 
θ. These samples are simulated from the full con-
ditional posterior distributions for p, Sem and Spm.
Following Equations (1) and (2) and considering 
k diagnostic tests, the conditional posterior distri-
butions for the components of θ needed for the 
Gibbs sampling algorithm are given by
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for m = 1, ..., k. This model is analogous to model 
developed by Joseph et al. (1995) [4].
Let wi be a sample observation of Wi , a vector 
of L covariates. For the sake of simplicity and 
without lack of generality, we assume that Ti is a 
random variable (with observation ti) related to result 
of only one diagnostic test, with Bernoulli distribution 
with success probability piSei+ (1−pi)(1−Spi), 
i = 1,…n. In the presence of a vector of covariates, 
let us assume the logit links for Sei ,  Spi  and pi , given 
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where l = 1, 2, 3, W0 i = 1, θ1i = Sei , θ 2i = Spi , θ3i = pi , 
for i = 1, ..., n. In this way, we have a vector of parameters 
given by β = (β 1, β 2, β 3), where β l = (β l0, β l1, ..., β lL), 
l = 1, 2, 3. Assuming prior independence among the 
parameters, we consider the prior densities for βl j with 
normal distribution with ﬁ  xed hyperparameters alj 
(means) and blj
2 (variances), l = 1, 2, 3, j = 0, 1, ..., L. 
The likelihood function for β is given by
sample. In each cycle of the algorithm is generated 
a new value for the latent variable G as (2).
In studies of the performance of two or more 
independent diagnostic tests applied to a selected 
group of individuals, where none of these tests can 
be considered the gold standard, a straightforward 
extension of this model can be used. Considering the 
three diagnostic tests, cervical cytology, VIA and HC II, 
where g is an observation of the latent variable G, 
given by (2). Combining the prior distributions 
with L(β ), we have the conditional posterior 
distributions for β given by
the vector of unknown parameters is now given by 
β = (β1, ..., β7), where βl = (βl0, βl1, ..., βlL), l = 1, ..., 7, 
are vectors of parameters related to the sensitivity 
and the speciﬁ  city of each test and the prevalence of 
where j = 0, 1, ..., L and β(β10) is the vector of all 
parameters except β10 (for example). Observe that 
we should simulate samples for all parameters 
considering the Metropolis-Hastings algorithm [47] 
since their conditional distributions are difﬁ  cult to 
cervical lesions. Let Tmi be a random variable with 
observation tmi related to test m, m = 1, 2, 3. Using 
logit link function to relate the vector Wi of L covari-
ates to the screening performance measures, i = 1, ...n, 
the likelihood function for β is now given by
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In this expression, the vectors of parameters β1, 
β2 and β3 are related to the sensitivities of the cer-
vical cytology, VIA and HC II, respectively; β4, β5 
and β6 are related to the speciﬁ  cities of the cervical 
cytology, VIA and HC II, respectively; and the 
vector β7 is related to the prevalence of cervical 
lesions. We consider the prior densities for βlj with 
normal distribution with ﬁ  xed hyperparameters alj 
(means) and blj
2  (variances), l = 1, .., 7, j = 0, 1, ..., L. 
Combining the prior distributions with L(β), we 
have the conditional posterior distributions for β 
and the Metropolis-Hastings algorithm is used to 
generate samples from the each parameter.
4. Data Set
The data set is from a European Commission 
funded ongoing study known as the LAMS (Latin 
American Screening) study, where PAP smear/
liquid-based cytology and screening colposcopy 
were compared with three optional screening tools 
(visual inspection with acetic acid or Lugol’s iodine 
and cervicography) and with Hybrid Capture II 
from conventional samples and from self-samples, 
in women at different risk for cervical cancer in 
three Brazilian arms (São Paulo, Campinas and 
Porto Alegre) and one Argentine arm (Buenos 
Aires). The study design and baseline data of the 
LAMS study were presented by Syrjanen et al. 
(2005) [20]. Partial results from the LAMS study 
were provided by Sarian et al. (2005) [21].
In the present study, we considered the data 
from Campinas, one of the three Brazilian arms of 
the LAMS study. From February to December 
2002, 1,195 women were recruited at a basic health 
unit and from July to December 2002, 221 women 
were recruited at the University Hospital (Centro 
de Atenção Integral à Saúde da Mulher-CAISM). 
Both services are situated in Campinas, a 969,396 
inhabitants city in Brazil’s southeast region. 
Among these 1.416 women, 809 women were 
eligible for the study related to the sensitivity and 
speciﬁ  city of three cervical cancer screening tests 
(cervical cytology, visual inspection with acetic 
acid and Hybrid Capture II) in the presence of 
covariates and in the absence of a gold standard 
and were willing to participate. Women were eli-
gible if they were between 18 and 60 years of age, 
if they had been submitted at all three diagnostic 
methods and if they had intact uterus. Patients 
previously subjected to treatment for condylomas 
or with history of current abnormal cytology were 
excluded. Women who presented with conﬁ  rmed 
immunossupression, immunodeﬁ  ciency or HIV 
infection, who had sexual intercourse or vaginal 
medication in the last three days were not included. 
Informed consent was obtained from all participant 
women. The study protocol was reviewed and 
approved by the Committee of Ethics in Research 
of the Medical Science School of the State Uni-
versity of Campinas.
Cervical cytology was collected after evaluation 
and treatment for possible infectious processes. 
Ayre spatulas and cervical brushes were used for 
these samplings. The samples were stained accord-
ing to the Papanicolaou method and evaluated 
using the Bethesda System [21]. Cytology was 
considered positive if showing cellular atypia, 
irrespective of their severity. Ecto- and endo-
cervical samples were collected for second gen-
eration Hybrid Capture (HC II) using sterile 
endo-cervical brushes supplied by Digene Diag-
nostics and processed following the instructions 
of the manufacturer (Digene Diagnostics Inc.). The 
HC-II is a molecular biological method that tests 
the presence of the HPV-DNA, through a chemolu-
minescent reaction. HC-II is commercialized as 
standard kits and it is based on a reaction of hybrid-
ization realized into several sorts of solutions with 
non-radioactive probes of known ribonucleic acids. 
Viral load was measured in relative light units 
(RLU/CO) and HC II results were categorized as 
negative if 1 RLU/CO and positive otherwise. 
After the collection of the cervical cytology and 
HC II, dilute 5 percent acetic acid was applied to 
the cervix. One minute afterwards, the cervix was 
illuminated with adapted spotlights (100 Watts) 
and naked-eye examined for acetowhite areas. The 
visual appearance was classiﬁ  ed according to the 
Atlas for Unaided Visual Inspection of the Cervix 
[22] using the categories: normal, atypical, intra-
epithelial neoplasia or suggestive of cervical 
cancer. Normal or atypical results were classiﬁ  ed 
as negative and intra-epithelial neoplasia or sug-
gestive of cervical cancer were classiﬁ  ed as posi-
tive. More details on the study protocol may be 
found in Syrjanen et al. (2005) [20].
5. Results
First of all, the sensitivity and speciﬁ  city of cervi-
cal cytology (T1), VIA (T2) and HC II (T3) were 
estimated by a Bayesian approach proposed by 
Joseph et al. (1995) [4]. This method was developed 
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for the situation where a reference test is not avail-
able and it has the assumption that the tests are 
conditionally independents. Seven parameters 
were estimated, including the prevalence of pre-
neoplasic or neoplasic lesions and the sensitivity 
and speciﬁ  city pairs relative to the three diagnostic 
methods under evaluation. An important feature of 
the Bayesian approach is the combination of the 
data obtained by the current sampling scheme with 
prior information about the parameters of interest. 
This prior information is quantitatively introduced 
in the statistical analysis and it can represent the 
pooled subjective opinions of the experts, or infor-
mation derived from the published literature. In 
the present study, we initially deﬁ  ned the prior 
information from the medical literature, using beta 
probability distributions.
The prior information about the sensitivity and 
the speciﬁ  city of cervical cytology was based on 
the systematic review of Nanda et al. (2000), who 
presented sensitivity for atypical squamous cells 
of undetermined signiﬁ  cance (ASC-US) or worse 
being ranged from 29 percent to 56 percent and 
speciﬁ  city from 97 percent from 100 percent [23]. 
The studies of Belinson et al. (2001) and of the 
University of Zimbabwe and JHPIEGO Cervical 
Cancer Project (1999) were used as references for 
the choice of the prior information about the sen-
sitivity and the speciﬁ  city for the VIA [25–26]. In 
these studies, the sensitivity of VIA for at least CIN 
II was estimated in 55 percent and 64 percent, 
respectively and the speciﬁ  city was estimated as 
76 percent and 67 percent, respectively. The prior 
information of the accuracy measures of HC II test 
was based on the studies of Schiffman et al. (2000) 
and Wright et al. (2000), who estimated sensitivi-
ties by 88.4 percent and 81.3 percent (at 1 RLU 
cut-off), respectively and speciﬁ  cities by 89.0 
percent and 84.5 percent, respectively [27–28].
However, the choice of informative prior dis-
tributions based only in a summary of previous 
studies can be a complex task, since each study has 
elements of subjectivity, error-proneness and pos-
sible potential for bias. Thus, a panel of experts on 
cervical cancer was asked to provide their best 
estimate for the sensitivities and speciﬁ  cities of the 
tests and the prior distributions that summarise the 
information provided by the literature review cor-
rected by the experts were derived. The assessment 
of beta distribution priors for each test parameter 
considered the method presented by Joseph et al. 
(1995) [4], where the hyperparameters are deﬁ  ned 
by matching the center of a range of plausible 
values of sensitivity and sensitivity with the mean 
of the beta distribution and matching the standard 
deviation of the beta distribution with one quarter 
of the total range. We considered a vague prior 
distribution for the prevalence of precursor cervi-
cal lesions (a Beta distribution with hyperparam-
eters 0.5 and 0.5, see [29]) motivated by a little 
background knowledge about this parameter.
The median age of the 809 women who 
participated of the study was 34 years. Approxi-
mately three quarters of these women lived with a 
partner (73.0 percent) and one-third had 8 or more 
years of education (33.3 percent). The majority 
self-reported to be white (67.2 percent) and 64.3 
percent reported not to be a smoker. Half of the 
women (50.3 percent) reported to have had only 
one lifetime sexual partner and almost three quar-
ters (72.9 percent) had initiated the sexual life in 
the teenage. Only 1.5 percent of the women entered 
in the study with less than one year since her ﬁ  rst 
sexual intercourse and the majority (86.1 percent) 
reported to have had only one sexual partner dur-
ing the last 12 months. The percentage of women 
who are pregnant at the time of the study was 
around 7.7 percent.
Based on the cases for which cervical cytology 
was available, 758 (93.7 percent) had normal 
results, 12 (1.5 percent) had low-grade squamous 
intraepithelial lesion (LSIL), 4 (0.5 percent) had 
high-grade squamous intraepithelial lesion (HSIL) 
and 35 (4.3 percent) were ASC-US. Table 1 shows 
the results of the three tests for the 809 available 
cases. For a Bayesian data analysis, the Gibbs 
sampler algorithm was run for 100,000 cycles, 
where the ﬁ  rst 20,000 were used to assess conver-
gence and the last 80,000 were used for inferences. 
For each parameter of interest, the arithmetic mean 
of these 80,000 Gibbs samples is a natural Bayes-
ian estimator. These arithmetic means are showed 
in Table 2, with the respective 95 percent credible 
intervals. Table 2 also shows positive and negative 
predictive values for each diagnostic test, calcu-
lated in each cycle of the Gibbs algorithm from the 
estimated sensitivities and speciﬁ  cities and the 
prevalence ﬁ  gures (a mathematical approach is 
presented by Altman and Bland [30]).
The results suggest a low sensitivity for cervical 
cytology to detect ASC-US or worse (53.6 percent) 
as well as for VIA (52.9 percent), but indicate a 
high sensitivity for the HC II (90.3 percent). All 
screening methods presented relatively high 
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speciﬁ  cities, 97.0 percent for cervical cytology, 
93.0 percent for VIA and 88.7 percent for the HC II. 
As is evident in Table 2, all methods presented very 
low positive predictive values (PPV) due to the 
low prevalence of cervical lesions [30]. Although 
with high sensitivity and speciﬁ  city, HC II did not 
present a high PPV (35.3 percent), which is similar 
to that estimated for VIA. On the other hand, all 
methods presented high negative predictive values 
(NPV) (Table 2). The prevalence of precursor 
lesion was estimated as 6.4 percent and this low 
prevalence naturally imply few diseased individu-
als and consequently low PPVs.
Another important result from the Bayesian 
model is related to the estimates for the expected 
value of true positives for each combination of the 
three screening methods, as shown in Table 3. This 
estimator is a numerical approximation and in this 
way it may accept decimals. The proportion of the 
predicted number of positives from the total of 
sampled individuals is the estimate of PPV. In 
Table 3, we notice that for 9 women, all three tests 
reported positive outcomes and the expected PPV 
is 98.6 percent. On the other hand, when all the 
tests are negative, it is expected that only 0.2 per-
cent of the women with this outcome will have 
cervical lesions.
Tables 4 and 5 shows as secondary results the 
sensitivities and speciﬁ  cities for each combination 
of the screening tests. Table 4 summarizes the 
results when the tests are evaluated in serial com-
bination (positive when both tests were positive 
and negative otherwise) and Table 5 summarizes 
the results when the tests are evaluated in parallel 
combination (positive when at least one of the 
tests was positive and negative otherwise). When 
the association between two tests is considered, 
the results of the third test are not considered. In 
Table 4, the serial combination between cervical 
cytology and visual inspection has a sensitivity of 
78.0 percent, which is higher than the sensitivity 
of each test individually (53.6 and 52.9 percent 
respectively, see Table 2). This result suggests an 
apparent improvement in sensitivity, but at a cost 
Table 1. Results of cervical cytology, VIA and HC II in 809 women who underwent all three tests.
Cervical cytology + Cervical cytology −
HC II + HC II − HC II + HC II − Total
VIA+ 9 2 15 35 61
VIA− 21 19 87 621 748
Total 30 21 102 656 809
Abbreviations: VIA: visual inspection with acetic acid; HC II: Hybrid Capture II.
Table 2. Bayesian estimates for sensitivities, speciﬁ  cities, positive and negative predictive values for each screen-
ing test, and for the prevalence of cervical lesions.
Test   %  95%  CI
Cervical cytology  sensitivity  53.6  42.1–65.0
 speciﬁ  city  97.0  95.5–98.4
 PPV  55.3  37.4–73.6
 NPV  96.8  94.8–98.3
Visual inspection
with acetic-acid     
 sensitivity  52.9  43.5–62.5
 speciﬁ  city  93.0  91.0–94.7
 PPV  34.0  22.4–46.2
 NPV  96.6  94.6–98.1
Hybrid Capture II  sensitivity  90.3  76.2–98.7
 speciﬁ  city  88.7  85.9–91.4
 PPV  35.3  22.8–48.8
 NPV  99.2  97.8–99.9
prevalence   6.4  3.9–9.3
Abbreviations: CI: credible interval; PPV: positive predictive value; NPV: negative predictive value.
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in speciﬁ  city, when these two tests are used jointly. 
However, this increase in sensitivity must be 
interpreted with caution. Franco [31] advised that 
nominal increase in sensitivity always occurs by 
chance whenever an adjunct test, as HC II, is used 
in combination with a conventional test, as Pap 
cytology, even if the complementary test was 
totally random with respect to the disease being 
evaluated.
In a second instance, we introduced in the model 
the age of the women (X ) as a continuous covari-
ate. The covariate W1 is given by () Xx − /10, 
wherex  is the sample mean of X . The quotient 10 
is only considered for avoiding numerical instabil-
ity related to large values in exponential functions 
present in the conditional posterior densities of 
interest. We also introduced in the model the 
variable W2, a dichotomous variable that denotes 
whether or not the woman is actually pregnant 
(1 if pregnant and zero otherwise). Firstly, we 
considered 13 the interaction between W1 and W2 
in the model. However, all interaction parameters 
were estimated to be close to zero (ranged from 
−0.031 to 0.009) and it were excluded from the 
ﬁ  nal model.
From the conditional densities for the 
parameters in β, we generated 100,000 Gibbs 
samples. From this chain, we discarded the ﬁ  rst 
20,000 (regarded as burn-in samples). The 
convergence of the Gibbs samples was monitored 
by standard existing methods [32] and the trace 
plots obtained are shown in Figure 1. The 
convergence was observed for all parameters. 
Prior distributions for the intercept parameters β10 
to β70 were assumed with ﬁ  xed hyperparameters 
based in estimates obtained in the previous 
analysis without covariates. For example, we 
noted that the estimated sensitivity of the cervical 
cytology was 0.536 (see Table 2), and considering 
the inverse of the logit function, the hyperparameter 
a10 is thus given by log (0.536/(1 – 0.536)). All 
the other hyperparameter values were chosen to 
have noninformative priors. Thus, we used an 
empirical Bayesian modelling approach [33]. For 
each parameter, we considered every 50th draw, 
which totalizes a sample of size 1, 600. Considering 
Table 4. Bayesian estimates of the sensitivities and speciﬁ  cities for the combinations between screening tests 
in serial mode*.
Combination between tests    %  95% CI
Cervical cytology + and VIA + sensitivity  78.0  70.3–84.8
 speciﬁ  city  90.2  87.9–92.4
Cervical cytology + and CH II + sensitivity 95.5 88.7–99.4
 speciﬁ  city  86.1  82.9–89.1
VIA + and CH II + sensitivity  95.4  88.5–99.4
 speciﬁ  city  82.5  79.3–85.6
All tests positive  sensitivity  97.9  94.5–99.7
 speciﬁ  city  80.1  76.6–83.4
*Positive when all tests were positive and negative otherwise.
Abbreviations: VIA: visual inspection of the cervix with acetic-acid; HC II: Hybrid Capture II; CI: credible interval.
Table 3. Estimates for the number of true positives for each combination of the screening methods and their 
expected positive predictive values.
   Test    Total of  Predicted  Expected
Cervical  VIA  HC II  sampled   number of   positive predictive
cytology     individuals  positives  value  (%)
+  +  + 9  8.87  98.6
+  +  − 2  0.93  46.7
+  −  + 21 17.33  82.5
+  −  − 19  1.37  7.2
−  +  + 15  9.85  65.6
−  +  − 35  0.97  2.8
−  −  + 87 10.39  11.9
−  −  − 621  1.19  0.2
Abbreviations: VIA: visual inspection with acetic acid; HC II: Hybrid Capture II.
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that a logit link was used, the regression 
coeffcients in β are interpreted as being the 
logarithm of the odds ratios (OR). These odds 
ratios represent an association measure between 
the variables W1 and W2 and the operating 
characteristics of the screening tests.
In Table 6, we have the posterior summaries for 
the exponential funcion of the parameters of inter-
est in β, interpreted as odds ratios. We observe that 
the 95 percent credible intervals for the parameters 
e
β11 to e
β 71 included the value 1, suggesting that 
there is no evidence for the effect of pregnancy in 
e
β12 and e
β52 Se and Sp measures for all tests. The 
parameters e
β12 and e
β 52 were estimated in 2.033 
and 1.615, respectively and its credibility interval 
does not include the value 1. This result suggests 
that the sensitivity and the specificity of VIA 
increases as the age of the women increases. In fact, 
in the medical literature several authors have 
described that methods for detection of precursor 
lesions of cervical cancer have different perfor-
mances according to the age of women [26, 34, 35]. 
The prevalence of cervical lesions, as expected, 
tends to increase as the age of the women increases 
(OR estimated in 0.483 and the respective 95% 
credible interval do not included the value 1). This 
effect of age on the prevalence is well-known in 
the medical literature since the disease is more 
incident in sexually active women.
6. Concluding Remarks
In this article, we introduced a Bayesian approach 
based on a Markov chain Monte Carlo (MCMC) 
algorithm that allows the performance measures 
estimations of diagnostic tests in the presence of 
covariates and when a gold standard is not 
available. An advantage of the proposed methodol-
ogy is the fact that the number of parameters to be 
estimated is not limited by the number of observa-
tions as it happens when we use the method intro-
duced by Hui and Walter [3]. We used the logit link 
function to relate the covariates linearly to the 
screening performance measures, but it is possible 
to use other link functions than the logit function, 
in according to the nature of the data. For com-
parison, we also adjusted Bayesian models to 
estimating the sensitivity and the speciﬁ  city of the 
cervical cancer screening tests here presented 
based on other link functions, as the log-log 
complementary function, but we do not observe 
signiﬁ  cant changes in the parameter estimates and 
its inferences (results not shown). However, a mis-
speciﬁ  ed model could arise from an incorrect link 
function and the use of model comparison mea-
sures, as the Deviance Information Criterion (DIC) 
of Spiegelhalter et al. [36], allow us to decide 
which of these functions give us the most appropri-
ate model. An advantage of the logit link function 
over other functions is that it provides estimates 
of odds ratios, a meaningful and well-known mea-
sure of association.
An important consideration in the use of the 
proposed model is its dependence on the prior 
information. In a sensitivity analysis, we noted, for 
example, that the prevalence of cervical lesions is 
increased when we used all non-informative prior 
distributions and other substantial changes in the 
sensitivity and speciﬁ  city. In the presented model, 
the lack of a gold standard is counterbalanced by 
the introduction of a latent variable G (2) that best 
describe the data simulating a reference test. This 
latent variable has a Bernoulli distribution with 
success probability given in function of the 
Table 5. Bayesian estimates of the sensitivities and speciﬁ  cities for the combinations between screening tests 
in parallel mode*.
Combination between tests    %  95%CI
Cervical cytology + or VIA + sensitivity  28.3  20.5–36.9
 speciﬁ  city  99.8  99.7–99.9
Cervical cytology + or CH II + sensitivity  48.3  36.4–60.3
 speciﬁ  city  99.7  99.4–99.8
VIA + or CH II + sensitivity 47.7  36.8–58.2
 speciﬁ  city  99.2  98.8–99.4
At least one test positive  sensitivity  25.6  17.8–34.2
 speciﬁ  city  99.98  99.96–99.99
*Positive when at least one of the tests was positive and negative otherwise.
Abbreviations: VIA: visual inspection of the cervix with acetic-acid; HC II: Hybrid Capture II; CI: credible interval.
Cancer Informatics 2008:642
Martinez et al
Cancer Informatics 2008:4 
(a)
-1,5
-1
-0,5
0
0,5
1
1,5
0 500 1000 1500
(b)
-1,5
-1
-0,5
0
0,5
1
1,5
0 500 1000 1500
(c)
0
0,5
1
1,5
2
2,5
3
3,5
0 500 1000 1500
(d)
2
2,5
3
3,5
4
4,5
5
5,5
0 500 1000 1500
(e)
2
2,5
3
3,5
4
0 500 1000 1500
(f)
1
1,5
2
2,5
3
3,5
0 500 1000 1500
(g)
-4
-3,5
-3
-2,5
-2
-1,5
-1
0 500 1000 1500
(h)
-2
-1,5
-1
-0,5
0
0,5
1
1,5
2
0 500 1000 1500
(i)
-2
-1,5
-1
-0,5
0
0,5
1
1,5
2
0 500 1000 1500
(j)
-2
-1,5
-1
-0,5
0
0,5
1
1,5
2
2,5
0 500 1000 1500
(k)
-2
-1,5
-1
-0,5
0
0,5
1
1,5
2
0 500 1000 1500
(l)
-1
-0,5
0
0,5
1
1,5
2
0 500 1000 1500
(m)
-1,5
-1
-0,5
0
0,5
1
1,5
0 500 1000 1500
(n)
-2
-1,5
-1
-0,5
0
0,5
1
1,5
2
0 500 1000 1500
(o)
-2
-1,5
-1
-0,5
0
0,5
1
1,5
0 500 1000 1500
(p)
-1
-0,5
0
0,5
1
1,5
2
0 500 1000 1500
(q)
-2
-1,5
-1
-0,5
0
0,5
1
1,5
0 500 1000 1500
(r)
-1,6
-1,2
-0,8
-0,4
0
0,4
0,8
0 500 1000 1500
(s)
-0,4
0
0,4
0,8
1,2
0 500 1000 1500
(t)
-0,8
-0,4
0
0,4
0,8
1,2
0 500 1000 1500
(u)
-1,6
-1,2
-0,8
-0,4
0
0 500 1000 1500
Figure 1. Trace plots of the sample values versus iteration for the parameters β10 (a), β20 (b), β30 (c), β40 (d), β50 (e), β60 (f), β70 (g), β11 (h), 
β21 (i), β31 (j), β41 (k), β51 (l), β61 (m), β71 (n), β12 (o), β22 (p), β32 (q), β42 (r), β52 (s), β62 (t) and β72 (u).43
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performance screening measures and its subjective-
ness from the respective prior distributions. 
Therefore, more accurate results would be given 
if we incorporate reasonable prior distributions 
based on prior knowledgement of clinical 
experts.
Although the proposed model is able to esti-
mate useful performance measures of serial and 
parallel combinations of the screening tests (see 
Tables 4 and 5), the relative gains in sensitivity 
and losses in speciﬁ  city can be misleading (see 
details in Franco e Ferenczy [37]). Macaskill et al. 
[38] argued that the expected number of additional 
true positive and false positive results (or true 
negative and false negative results) can be used 
as the basis for deciding whether to use tests in 
combination when neither the combined nor a 
component test shows superior test performance 
based on their likelihood ratios. Thus, the com-
parison between the likelihood ratios for two 
competing tests can be used to assess the incre-
mental gain from an adjunct test. An extension of 
the presented Bayesian model considering the 
inclusion of parameters that describe the com-
parison between likelihood ratios as proposed by 
Macaskill et al. [38] should be also considered in 
future studies.
The major shortcoming of the Bayesian 
estimating method resides in the necessary pre-
sumption that the diagnostic tests are statistically 
and conditionally independent. This presupposition 
might not be invariably true [39] and alternative 
methods were proposed by Espeland and Handelman 
(1989); Yang and Becker (1997) and Dendukuri 
and Joseph (2001) to address those situations 
[40, 41, 13]. However, all of these approaches 
address situations in which the correlation between 
two screening tests is considered and extensions 
for three or more tests are not found in the litera-
ture. Bayesian models that include the conditional 
dependence between multiple screening tests 
should be considered in future studies.
It is also important to point out that the diag-
nostic tests evaluated in this study have some 
inherent ﬂ  aws. The lack of accuracy and reproduc-
ibility of cervical cytology is explained by the 
biological variability, sample quality, subjective 
interpretation of morphological abnormalities and 
examiners fatigue derived from repetitive proce-
dures [42]. VIA requires training, although an 
obvious trend towards examiner subjectivity is 
always present. HC II results are more reproducible 
than those of VIA and cervical cytology.
Thus, VIA suggested by Belinson et al. (2001) 
as a screening method is likely to assume a central 
role in the prevention of cervical cancer in many 
countries. This simple and inexpensive method 
does not require complex technical supplies and it 
allows diagnosis and treatment at a single visit 
[25]. Coste et al. (2003) evaluated the performances 
of conventional cytology, liquid-based cytology 
and HC II in detecting cervical lesions with a 
sample of 1,757 women, with a combination of 
colposcopy and biopsy as the gold standard [43]. 
This impressive number of colposcopies and biop-
sies certainly reduced the veriﬁ  cation bias, but our 
results still substantiate the view that this type of 
statistical modelling could provide reliable results 
Table 6. Posterior odds ratios as association measures between pregnancy and age and the performance 
measures of the cervical cytology, VIA and HC II.
parameter measure  mean  SD    95%  CI
e
β 11  effect of pregnancy on Se1 1.142 0.566 0.420  2.496
e
β 21  effect of pregnancy on Se2 1.079 0.502 0.400  2.291
e
β 31  effect of pregnancy on Se3 1.214 0.667 0.413  2.864
e
β 41  effect of pregnancy on Sp1 1.105 0.528 0.416  2.384
e
β 51  effect of pregnancy on Sp2 1.626 0.710 0.670  3.425
e
β 61  effect of pregnancy on Sp3 0.840 0.343 0.381  1.692
e
β 71  effect of pregnancy on P 1.168  0.509  0.479  2.451
e
β 12  effect of age on Se1 0.973  0.318  0.481  1.694
e
β 22  effect of age on Se2 2.033  0.699  1.013  3.737
e
β 32  effect of age on Se3 0.914  0.364  0.393  1.856
e
β 42  effect of age on Sp1 0.804  0.202  0.469  1.239
e
β 52  effect of age on Sp2 1.615  0.282  1.131  2.272
e
β 62  effect of age on Sp3 1.422  0.238  0.996  1.925
e
β 72  effect of age on P 0.483  0.109  0.313  0.738
Abbreviations: SD: standard deviation; CI: credibility interval.
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using fewer patients either subjected to the gold 
standard or simply with no gold standard. This is 
because of the natural inﬂ  uence of the disease 
prevalence on the values of PPV and NPV. The 
prevalence of histologically conﬁ  rmed cervical 
abnormalities is necessarily low in a healthy 
population and screening tests usually have low 
PPV and high NPV, because true positives are rare 
and true negatives are abundant [30].
Three Indian studies in the late 1990s provided 
evidence supporting VIA as a viable alternative to 
cytology as a primary screening test [44–47]. In 
one of these studies, Londhe et al. [45] evaluated 
12,372 women that underwent VIA, Pap smear and 
colposcopy in a gynecology outpatient clinic. VIA 
identiﬁ  ed 78 percent of high-grade cervical lesions 
diagnosed with colposcopy, 3.5 percent more than 
were identiﬁ  ed by cytology. In a 1998 Indian study 
[46] involving 3,000 women, VIA and cytology 
(done only by cytotechnicians) performed very 
similarly (sensitivity ratio of 1.05) in terms of 
detecting moderate/severe dysplasia. The approx-
imate speciﬁ  city of VIA in this study was 92.2 
percent compared with 91.3 percent for cytology. 
In a third Indian study published in 1999, 
Sankaranarayan et al. found that VIA detected 
signiﬁ  cantly more moderate/severe lesions than 
cytology but its speciﬁ  city was signiﬁ  cantly lower 
[47]. A large-scale study (over 10,000 women) in 
Zimbabwe compared the performance of VIA and 
the Pap smear in the hands of nurse midwives in 
primary health clinics. Phase II of this study was 
the ﬁ  rst to provide direct estimates of sensitivity/
speciﬁ  city because all women testing negative or 
positive were offered the reference standard (col-
poscopy and biopsy, if indicated). In this study, the 
sensitivity of VIA (for high-grade positivity) was 
1.75 times higher than that of cytology (76.7 vs. 
44.3 percent respectively) whereas the speciﬁ  city 
was 1.4 times lower [26].
The studies mentioned above yielded valuable 
information regarding the performances of VIA 
and cytology. Our Bayesian estimates provided 
performance values that can be compared with the 
results obtained in the standard manner, that is, 
with the use of a gold standard. In our estimates, 
VIA and cytology had similar sensitivity and 
speciﬁ  city, as well as PPV and NPV. These ﬁ  gures 
contradict the previously published direct estimates 
that reported a superiority of VIA in detecting 
cervical lesions [46,47]. These differences may be 
attributable to methodological incompatibilities in 
sample collection or processing and, as mentioned 
before, to the inherent diff iculties derived from the 
variability of cytology and VIA interpretation.
The performance of HPV test in screening set-
tings has been extensively studied, but to a lesser 
extent in comparison with VIA and cytology. 
Denny et al. (2000) published their data on 2,944 
women subjected to VIA, cytology and HPV test-
ing. In this study, VIA and HPV (1 RLU) were 
similar to cytology in their performance of detect-
ing high-grade lesions, but VIA yielded the largest 
number of false-positives among the three testing 
modalities [48]. More recently, these same authors 
[49] published a methodologically similar study 
testing cervicography, VIA, HPV test and cytol-
ogy. In this study, 2,754 previously unscreened 
South African women were subjected to the four 
exams and VIA detected signiﬁ  cantly more high-
grade lesions as compared to the other screening 
tests.
The shortcomings of the tests (as reproducibil-
ity, subjective interpretation of results and required 
training of professional) did not hamper the 
Bayesian estimates but, in contrast, would enhance 
the search for realistic estimating equations. Thus, 
the inclusion of covariates (or control variables) 
should be encouraged in studies designed for the 
evaluation of estimating methodologies. According 
to Parmigiani (2002), prediction models used to 
support the clinical and health policy decision 
making need to consider the course of the disease 
over an extended period of time and draw evidence 
from a broad knowledge base, including epide-
miological cohort and case control studies, ran-
domized clinical trials, expert opinions and more 
[50]. In these cases, Bayesian decision theory and 
the tools typically used to describe the uncertainties 
involved could be extremely useful. The age of the 
patient is an important covariate in the study of 
cervical carcinoma precursor lesions. Koss [51] 
and Schiffman et al. [27,44] did not recommend 
the use of HPV testing in young women because 
the prevalence of the virus is exceptionally high in 
this group and the majority of such infections will 
spontaneously regress in the short term. Cervical 
lesions only develop in the presence of persistent 
HPV infections, thus HPV testing in young women 
will reveal an excessive number of HPV positive 
subjects that will never develop HPV-related cervi-
cal precancer lesions.
We can conclude that the estimated perfor-
mances of VIA, HC II and cytology clearly show 
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that the Bayesian method is a remarkable tool for 
validating diagnostic tests when a gold standard is 
available for a very limited number of cases or not 
available at all.
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